Table TDI-11. Characteristics of new clients treated for drug problems: demographics and main drug at treatment in 2002 or most recent year available. Part (ii) Main drug (percentage) and of those the percent injecting it (italics)
| Country | Opiates | % inj | Cocaine | % inj | Amphet amines | % inj | Ecstasy | Hallucin ogens | % inj | Cannabis | Others | ||
| Belgium | (1) | 21 | 7 | 5 | 5 | 14 | 3 | 3 | 1 | 0 | 44 | 12 | |
| Czech Republic | (2) | 16.7 | 81.6 | 0.1 | na | 50.6 | 81.6 | 4.1 | 0.4 | 5 | 22.7 | 5.4 | |
| Denmark | (3) | 35 | 28 | 4 | 7 | 8 | 5 | 2 | 0 | 0 | 33.6 | 9 | |
| Germany | (4) | 30 | na | 7 | na | 10 | na | na | 1 | na | 48 | 4 | |
| Greece | 84.3 | 56.3 | 1.5 | 11.5 | 0.1 | 0 | 0.6 | 0.1 | 0 | 11 | 2.4 | ||
| Spain | 28 | 20 | 42 | 6 | 1 | 6 | 2 | 0.1 | 9 | 23 | 3.9 | ||
| France | (5) | 63.4 | 20.6 | 5.2 | 10.4 | 0.3 | 8.3 | 1.3 | 0.4 | 0 | 25.6 | 3.8 | |
| Ireland | (6) | 47.4 | 99.6 | 1.7 | 0 | 1 | 0.4 | 10.6 | 0.4 | 0 | 35.4 | 3.5 | |
| Italy | (7) | na | na | na | na | na | na | na | na | na | na | na | |
| Latvia | (8) | 69.6 | 93.7 | 0.9 | 0 | 10 | na | 0 | 0.5 | 0 | 6.4 | 12.6 | |
| Lithuania | (9) | 83.9 | na | 0.2 | na | 3 | na | na | 0.2 | na | 0.2 | 12.5 | |
| Luxembourg | na | na | na | na | na | na | na | na | na | na | na | ||
| Hungary | (11) | na | na | na | na | na | na | na | na | na | na | na | |
| Netherlands | (12) | 22 | 18 | 41 | 1 | 4 | 4 | 2 | 0 | 0 | 28 | 3 | |
| Austria | (13) | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Portugal | (14) | na | na | na | na | na | na | na | na | na | na | na | |
| Slovenia | 73.9 | 99.6 | 0.8 | 0 | 0.2 | 0 | 0.8 | 0 | 0 | 22.7 | 1.6 | ||
| Slovakia | 51.6 | 78.6 | 0.6 | 0 | 14.5 | 43.4 | 0.5 | 0.8 | 0 | 17.9 | 14.1 | ||
| Finland | 21 | 82.8 | 0.3 | 82.1 | 31.7 | 65.8 | 1.4 | 0 | 0 | 39.6 | 6 | ||
| Sweden | (15) | 22 | 9 | 3 | 0 | 19 | 18 | 3 | 0 | 0 | 35 | 18 | |
| United Kingdom | (16) | na | na | na | na | na | na | na | na | na | na | na | |
| Notes: | |||||||||||||
| Data were not available for: Estonia, Cyprus, Malta, Poland and Norway. | |||||||||||||
| Injecting as a route of administration is not reported for cannabis. | |||||||||||||
| Belgium | (1) | Data refer only to outpatient treatment centres. Last data available refer to 1999. | |||||||||||
| Czech Republic | (2) | Data refer to all treatment centres. | |||||||||||
| Denmark | (3) | Injecting use for opiates refers only to heroin, and cocaine only to cocaine CIH. For distribution by main drug only clients attending outpatient centres. | |||||||||||
| Germany | (4) | Data only refer to outpatient treatment centres; information about injecting use is not available. Amphetamines also include ecstasy. | |||||||||||
| France | (5) | The last available data on treatment demand are reported, referring to the annual census on clients in treatment carried out in November 1999. | |||||||||||
| Ireland | (6) | Last data available refer to 2000. | |||||||||||
| Italy | (7) | Data only refer to outpatient treatment centres; information about injecting opiate use refers only to heroin, for cocaine only to cocaine CIH. | |||||||||||
| Latvia | (8) | Data refer only to outpatient treatment centres. | |||||||||||
| Lithuania | (9) | Amphetamines include all stimulants. | |||||||||||
| Luxembourg | (10) | Data on first treatment only partially available. | |||||||||||
| Hungary | (11) | 39% of clients are reported to use hypnotics/sedatives, 18% other substances. | |||||||||||
| Netherlands | (12) | Data refer only to outpatient treatment centres. | |||||||||||
| Austria | (13) | Data refer to clients in substitution treatment only; figures for opiates as main drug and injecting use are consequently 100%. | |||||||||||
| Sweden | (15) | Data refer only to outpatient treatment centres. | |||||||||||
| United Kingdom | (16) | Data relate to the period from 1 April 2001 to 31 March 2002 for Scotland and Northern Ireland; for England and Wales six months data ending 30 September 2000 plus six months data ending 31 March 2001. | |||||||||||
| Sources: 2003 Reitox national reports, Standard table 3, see [Table TDI-10 Part (iii)] for details on sources. | |||||||||||||
